GRI Bio (GRI) investor relations material

Executive summary

• Clinical-stage biopharma focused on therapies for inflammatory, fibrotic, and autoimmune disorders, with lead candidate GRI-0621 targeting severe fibrotic lung diseases such as IPF; Phase 2a trial met primary and secondary endpoints, showing safety, biomarker improvements, zero cough, 60% lower treatment-related diarrhea, and no serious adverse events in the active arm, even with higher nintedanib use.

• GRI-0621 demonstrated improvements in lung function, immune modulation, anti-fibrotic activity, and epithelial repair, supporting its differentiated therapeutic profile.

• GRI-0803, a novel oral agonist for autoimmune disorders, is in preclinical development, with IND-enabling studies planned for 2026 and pipeline expansion into autoimmune indications with high unmet need.

• No material legal proceedings or changes in risk factors reported.

Financial highlights

• Net loss for Q1 2026 was $2.0 million, improved from $3.0 million in Q1 2025.

• Operating expenses decreased to $2.0 million from $3.1 million year-over-year, driven by lower R&D costs after Phase 2a trial completion.

• Cash and cash equivalents were $11.0 million as of March 31, 2026, up from $8.2 million at December 31, 2025.

• Accumulated deficit reached $53.7 million.

Outlook and guidance

• Existing cash expected to fund operations into Q2 2027, assuming only preliminary work on Phase 2b trial; substantial additional capital required to complete Phase 2b.

• Plans to raise further capital through equity, debt, or partnerships; substantial doubt remains about ability to continue as a going concern without new funding.

• Advanced clinical development planning for GRI-0621 is underway for potential regulatory pathways in the US and Europe.